Diabetic Ketoacidosis (DKA) Initial Emergency Management
DKA is managed with immediate IV fluids, prompt IV insulin, aggressive electrolyte monitoring with potassium replacement, and identification of the precipitating cause [1], JBDS DKA guideline (PDF).
Treatment is delivered using a fixed DKA pathway with frequent reassessment to ensure biochemical improvement and safe insulin/potassium administration [1], JBDS DKA guideline (PDF).
Step 1: Immediate Assessment and Monitoring
DKA severity and complications should be assessed at presentation, including hemodynamic status, level of consciousness, and respiratory status [1].
Continuous monitoring should be used for vital signs and urine output when feasible JBDS DKA guideline (PDF).
Venous blood gas and electrolytes should be checked early and repeated frequently during the first hours of therapy JBDS DKA guideline (PDF).
Step 2: Diagnostic Confirmation and Baseline Testing
DKA should be confirmed with blood glucose, ketones (preferably β-hydroxybutyrate or ketonemia/ketonuria), and acid–base status JBDS DKA guideline (PDF).
Electrolytes should be obtained at baseline including potassium and bicarbonate-derived variables, plus renal function to guide fluid and potassium therapy JBDS DKA guideline (PDF).
Precipitating causes should be evaluated early, including infection, missed insulin, and myocardial events [1].
Step 3: IV Fluids (Restore Perfusion First)
Isotonic saline or balanced crystalloid should be started promptly after diagnosis [1].
The initial fluid rate should be 500–1,000 mL/h during the first 2–4 hours in adults without renal or cardiac compromise [1].
Caution is required for rapid fluid replacement in higher risk patients for fluid overload, including older adults, pregnancy, and those with heart or kidney disease [1].
Step 4: Start IV Insulin as Early as Possible
Insulin therapy should be initiated as soon as possible after diagnosis [1].
A fixed-rate intravenous insulin infusion should be used for DKA [1].
Insulin can be given as regular human insulin or rapid-acting insulin analogs when paired with aggressive fluid management and close monitoring [2].
Step 5: Potassium Management With Insulin Titration
Potassium replacement should be guided by serum potassium measured early and repeatedly during treatment [1], JBDS DKA guideline (PDF).
Potassium should be withheld if serum potassium is low until replacement is started and potassium is safely repleted JBDS DKA guideline (PDF).
Because potassium tends to fall as ketoacidosis improves with insulin, potassium should be closely monitored during the insulin infusion JBDS DKA guideline (PDF).
Step 6: Dextrose Addition and Insulin Dose Adjustment
Glucose should be monitored frequently during insulin therapy JBDS DKA guideline (PDF).
When glucose falls to around 14 mmol/L (≈252 mg/dL) or lower, IV dextrose should be started to permit continued insulin delivery for ketone clearance JBDS DKA guideline (PDF).
The insulin infusion rate should be reduced when glucose is falling too rapidly or after glucose reaches the target range that increases hypoglycemia risk JBDS DKA guideline (PDF).
Step 7: Monitoring Response and Adjusting Therapy
Venous pH and bicarbonate should be monitored and insulin adjusted if metabolic improvement is inadequate JBDS DKA guideline (PDF).
If bicarbonate is not rising at an expected rate, the insulin infusion rate should be increased in hourly increments JBDS DKA guideline (PDF).
Electrolytes should be rechecked every 2–4 hours during therapy in many protocols, with more frequent testing when instability occurs ADA 2001 hyperglycemic crises review.
Step 8: Bicarbonate Avoidance in Most Cases
Bicarbonate is generally not recommended because it has not demonstrated outcome improvement in resolution of acidosis or clinical endpoints in DKA [3], ADA hyperglycemic crises guideline text.
Step 9: Criteria for DKA Resolution
Resolution is commonly defined by serum bicarbonate ≥18 mEq/L and venous pH >7.3 with normalization of glucose criteria used for transition decisions ADA 2001 hyperglycemic crises review.
Ketones should be trending down to a safe range before stopping IV insulin to prevent recurrence ADA 2001 hyperglycemic crises review.
Step 10: IV-to-SQ Insulin Transition and Ongoing Care
IV insulin should not be stopped abruptly without adequate basal insulin coverage because rebound hyperglycemia or recurrent ketoacidosis can occur ADA 2001 hyperglycemic crises review.
Basal insulin should be administered 2–4 hours before IV insulin is discontinued to prevent recurrence [3].
Precipitating causes should be treated concurrently, including infection management and insulin adherence interventions [1].